Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CHRS

Coherus Oncology, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CHRS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Coherus Oncology, Inc. (NASDAQ: CHRS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-11-03 01:34 UTC.

What Coherus Oncology, Inc. does

Coherus Oncology is a fully integrated commercial-stage oncology company focused on immuno-oncology medicines following recent divestitures of its biosimilar businesses. The company commercializes LOQTORZI, an FDA-approved anti-PD-1 antibody developed with Junshi Biosciences for treating nasopharyngeal carcinoma, which it launched in the United States and is the only immune checkpoint inhibitor of its kind commercially available in the country for these indications.

Summarized from Coherus Oncology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity275.39%

Revenue, margins & earnings

FY2021: net loss $287M on revenue $327M$327MFY2021FY2022: net loss $292M on revenue $211M$211MFY2022FY2023: net loss $238M on revenue $257M$257MFY2023FY2024 Revenue: $26M — margin split not shown (non-operating gains)$26MFY2024FY2025 Revenue: $42M — margin split not shown (non-operating gains)FY2025: net income $168M exceeded revenue $42M by $126M — non-operating gains (e.g. asset sales), not operating profit$42MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-09
Most recent filed transactions — June 2026:
  • 2026-06-09DirectorAward30,000—
  • 2026-06-09DirectorStock Option (Right to Buy)Award60,000—
  • 2026-06-09DirectorStock Option (Right to Buy)Award60,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Coherus Oncology, Inc. do?

Coherus Oncology is a fully integrated commercial-stage oncology company focused on immuno-oncology medicines following recent divestitures of its biosimilar businesses.

When did CHRS last file with the SEC?

Coherus Oncology, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-11-03 01:34 UTC. This page is also available as JSON at /api/data?ticker=CHRS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CHRS and 5,000+ tickers.

Create a free account — keep CHRS
For your agent
GET /api/data?ticker=CHRS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt